JW ShinyakJW신약
067290 · KOSDAQ · ₩067290 · JW신약
- Market cap
- ₩132B
- Enterprise value
- ₩137B
- P/E
- 12.4×
- P/B
- 3.2×
- Dividend yield
- 0.0%
- ROE
- 26.1%
- Net margin
- 12.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−45.6% from the high
₩1,246Today: ₩2,315 – ₩2,375₩4,335
Returns
- 1W−6.7%
- 1M−24.8%
- 3M+39.6%
- 6M+14.0%
- YTD+10.8%
- 1Y+74.8%
- Volume today
- 849,544
- 0.3× the 20-day average
- Traded today
- ₩2B
- Listed shares
- 56,037,103
- EPS (12 months)
- ₩190
- Earnings yield 8.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-26.2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
JW Shinyak stock overview
JW Shinyak (JW신약, KRX: 067290) is listed on KOSDAQ, in the Biotech & Pharma sector. JW Pharmaceutical's subsidiary JW Shinyak manufactures and sells prescription and over-the-counter medicines, including antifungal and urology products, with a focus on the clinic market in internal medicine, dermatology, pediatrics, urology and otolaryngology. Its shares closed at ₩2,360 on Oct 27, 2026, up 2.39% on the day, giving it a market value of ₩132B.
Key facts
- Market cap
- ₩132B
- Sector
- Biotech & Pharma
- Latest price change
- +2.39%
- As of
- Oct 27, 2026
- Main business
- JW Pharmaceutical's subsidiary JW Shinyak manufactures and sells prescription and over-the-counter medicines, including antifungal and urology products, with a focus on the clinic market in internal medicine, dermatology, pediatrics, urology and otolaryngology.
Quick answers about JW Shinyak
- What does JW Shinyak do?
- JW Pharmaceutical's subsidiary JW Shinyak manufactures and sells prescription and over-the-counter medicines, including antifungal and urology products, with a focus on the clinic market in internal medicine, dermatology, pediatrics, urology and otolaryngology. Its customers are hospitals, clinics and pharmacies. Its main production plant is in Pyeongtaek, Gyeonggi Province, South Korea.
- What is the market cap of JW Shinyak?
- The market capitalisation of JW Shinyak was ₩132B at the close on Oct 27, 2026.
- Who are the largest shareholders of JW Shinyak?
- According to the latest official filings, the largest reported holders are JW Holdings (30.74%, as of Feb 9, 2026); Dimensional Emerging Core Equity Market ETF (0.04%, as of Jul 31, 2026); Lim Seung-yong (0.03%, as of Feb 7, 2025).
- When is the next earnings report from JW Shinyak?
- Korean companies rarely announce results dates in advance. Based on when JW Shinyak filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
JW Pharmaceutical's subsidiary JW Shinyak manufactures and sells prescription and over-the-counter medicines, including antifungal and urology products, with a focus on the clinic market in internal medicine, dermatology, pediatrics, urology and otolaryngology. Its customers are hospitals, clinics and pharmacies. Its main production plant is in Pyeongtaek, Gyeonggi Province, South Korea.
Written by AI from the company's latest annual report.
- Korean name
- JW신약
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김용관
- Founded
- Aug 1981
- Listed
- Feb 2003
- Listed shares
- 56,037,103
- Fiscal year ends
- Month 12
- Website
- www.jw-shinyak.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earningsAug 12, 2026
- Securities Issuance Results (Voluntary Disclosure)May 22, 2026
- Securities Issuance Results (Voluntary Disclosure)May 22, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityMay 22, 2026
Titles in Korean until English translations are added.
Also known as: JW Shinyak / JW신약 / 067290 / KRX:067290
Source: KRX statistical information